RAAPID Earns Microsoft Healthcare AI Certification, Strengthening Enterprise-Grade Risk Adjustment Solutions
The certification strengthens RAAPID's position as the trusted partner for health plans facing intensified CMS RADV audits and the transformation to value-based care. RAAPID's solutions, available through
"This Microsoft certification recognizes our commitment to delivering secure, trusted, and clinically impactful AI solutions for healthcare," said
RAAPID's Novel Clinical AI Platform addresses critical industry challenges through three flagship solutions: the RADV Audit Solution, which transforms high-stakes audits into predictable processes; the Retrospective Risk Adjustment Solution, which creates a single source of truth for member risk; and the Prospective Risk Adjustment Solution, which enables proactive care gap closure at the point of care. All solutions are deployed within customers' Azure tenants, ensuring that PHI never leaves their infrastructure.
Healthcare organizations using RAAPID report 5x+ return on investment, with
About RAAPID
RAAPID develops AI-powered risk adjustment solutions for healthcare payers, providers, and supporting organizations. The company's HITRUST-certified platform uses Neuro-Symbolic AI to identify chronic conditions, determine HCC codes, and provide explainable documentation for complete audit defense. Backed by M12 (Microsoft's venture fund), RAAPID serves organizations participating in Medicare Advantage, ACA, Medicare ACO, and Medicaid programs with both retrospective and prospective risk capture capabilities. Founded by healthcare technology veterans with over 20 years of experience, RAAPID is headquartered in
Learn more at www.raapidinc.com.
Contact
Director - Marketing
(502) 699-3044
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/raapid-earns-microsoft-healthcare-ai-certification-strengthening-enterprise-grade-risk-adjustment-solutions-302576721.html
SOURCE RAAPID INC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
- Golden State Dermatology Expands into Colorado with Acquisition of Summit Dermatology
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share